Objective: Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. We aim to meta-analyse and compare the effect of aliskiren with ramipril by measuring mean difference in systolic blood pressure (mdSBP) and mean difference in diastolic blood pressure (mdDBP).
Methods: The search was conducted using the PubMed and Cochrane databases for eligible randomized clinical trials (RCTs) to perform a meta-analysis from January 2000 to May 2024. RCTs that included hypertensive patients who were under either aliskiren or ramipril treatment were included in the analysis. The risk of bias was evaluated using RoB 2.0. This study is registered with PROSPERO: CRD42024577105.
Results: Four studies were included: two studies were carried out for 2 months, and two were carried out for 6 months, including 693 and 329 patients, respectively, with mild to moderate hypertension and a mean age of 55.2 years. After 2 months, mdDBP was found to be significant (mdDBP=0.85mmHg, 95% CI: 0.73-0.97, I=0%), but mdSBP was found to be non-significant (mdSBP=0.0mmHg, 95% CI: -0.17-0.17, I=0%). There was a significant difference in the mdSBP (mdSBP=3.15mmHg, 95% CI: 2.13-4.17, I=84%) and mdDBP (mdDBP=1.2mmHg, 95% CI: 1.09-1.31, I=0%) at 6 months.
Conclusion: Aliskiren provides, in the short term, a slight improvement in BP in non-elderly hypertensive patients without diabetes or previous cardio-cerebrovascular disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hipert.2024.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis.
Hipertens Riesgo Vasc
December 2024
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia, Hamdard, New Delhi 110062, India.
Objective: Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. We aim to meta-analyse and compare the effect of aliskiren with ramipril by measuring mean difference in systolic blood pressure (mdSBP) and mean difference in diastolic blood pressure (mdDBP).
Methods: The search was conducted using the PubMed and Cochrane databases for eligible randomized clinical trials (RCTs) to perform a meta-analysis from January 2000 to May 2024.
Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats.
Endocrinol Diabetes Metab
April 2021
Faculty of Medicine, Cairo University, Giza, Egypt.
Objectives: Worldwide, diabetic neuropathy (DN) is a major complication of diabetes mellitus. The direct renin inhibitor aliskiren is recognized as a treatment for cardiovascular disease in diabetic patients, but little is known about its potential benefits in cases of diabetic neuropathy. Accordingly, we investigated the effects of aliskiren (ALIS) and gliclazide (GLZ) and their combination therapy on peripheral neuropathy in streptozotocin-induced diabetic rats.
View Article and Find Full Text PDFRenin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Cochrane Database Syst Rev
October 2020
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada.
Background: Renin inhibitors (RIs) reduce blood pressure more than placebo, with the magnitude of this effect thought to be similar to that for angiotensin converting enzyme (ACE) inhibitors. However, a drug's efficacy in lowering blood pressure cannot be considered as a definitive indicator of its effectiveness in reducing mortality and morbidity. The effectiveness and safety of RIs compared to ACE inhibitors in treating hypertension is unknown.
View Article and Find Full Text PDFEffect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.
J Hypertens
January 2021
Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia.
Objective: We tested the hypothesis that chronic treatment with the direct renin inhibitor aliskiren improves vascular function in resistance and conduit arteries of type two diabetic and hypertensive patients.
Method: Sixteen patients with mild essential hypertension and with a previous diagnosis of noninsulin-dependent diabetes mellitus were included in the study. Patients were then randomized to aliskiren (150 mg once daily, n = 9), or ramipril (5 mg once daily, n = 7).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!